Apollomics Inc., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The company seeks to have the registration become effective on May 29, 2024, at 4:00 p.m. Eastern Time. This request was made in accordance with Rule 461 of Regulation C under the Securities Act of 1933. Apollomics has indicated that the effective date may be adjusted if necessary, based on further communication with the SEC. The company's legal counsel, Ryan Coombs from O'Melveny & Myers LLP, is the primary contact for this matter, with Yoon-jee Kim available in his absence.

Apollomics Inc., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The company seeks to have the registration become effective on May 29, 2024, at 4:00 p.m. Eastern Time. This request was made in accordance with Rule 461 of Regulation C under the Securities Act of 1933. Apollomics has indicated that the effective date may be adjusted if necessary, based on further communication with the SEC. The company's legal counsel, Ryan Coombs from O'Melveny & Myers LLP, is the primary contact for this matter, with Yoon-jee Kim available in his absence.